AMG-305 is under clinical development by Amgen and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I drugs for Cervical Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AMG-305’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Monoclonal antibody is under development for the treatment of pancreatic ductal adenocarcinoma (PDA), solid tumor, colorectal cancer, non-small cell lung cancer, mesothelioma, pancreatic cancer, gastric cancer, head and neck cancer, cervical carcinoma, uterine carcinoma, epithelial ovarian cancer, head and neck cancer squamous cell carcinoma and triple-negative breast cancer. The drug candidate is a bi-specific monoclonal antibody construct with half-life extension (MSLN HLE BiTE) and acts by targeting cells expressing mesothelin (MSLN) and CD3. It is being developed based on BiTE technology. It is administered through intravenous rute.
Amgen is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines in therapeutic areas of cardiovascular, oncology/hematology, inflammation, bone health, neurological disorders and nephrology. The company develops products using advanced human genetics to analyze the difficulties of disease and understand the fundamentals of human biology. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels and through partnerships with other companies. The company has presence in Asia Pacific, Europe, Middle East, North America and Australia. Amgen is headquartered in Thousand Oaks, California, the US.
For a complete picture of AMG-305’s drug-specific PTSR and LoA scores, buy the report here.